covid-19.
Conditions
Interventions
Intervention 1: Intervention group: They receive 4 capsules of curcumin 40 mg daily made by Elixir Nano Drug Company for 14 days. Intervention 2: Control group: receive 4 placebo daily for 14 days.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: They have a positive PCR test or lung involvement in the imaging and 2- Hospitalized patients who are non-intubated. 3- They are over 18 years old .4- They have filled in the informed consent form5. 5-They are not pregnant or breastfeeding.6-They do not have gallbladder inflammation or active gastrointestinal ulcers.7. They do not have hemophilia or coagulation disease.8- renal failure with GFR <30 ml / min or dialysis patients.9- Signing informed written consent.10. Not participating in other clinical trials at the same time 11.cancer patients
Exclusion criteria
Exclusion criteria: 1-Patients who are allergic to turmeric or curcumin.2- renal disease "GFR <30 ml / min" or dialysis patie.3-Patients who do not take more than a quarter of curcumin supplements during the study period.4- Connecting the patient to the ventilator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Albumin, ferritin,CRP, ESR, interleukin 6,WBC,total lymphocyte count(TLC) Alanine Aminotransferase(ALT)(ALT),Aspartate Amino transferase(AST),LDH, resperatory oxygen saturation (SpO2) Nutritional Risk Index (NRI). Timepoint: The first day of study, the fourteenth day of study. Method of measurement: Blood test, Nutritional Risk Index questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactseyed jalil masoumi
Shiraz University of Medical Sciences
Outcome results
None listed